InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabet...(been designed to provide a safer therape...)

Date:9/30/2009

been designed to provide a safer therapeutic tool for physicians and patients, which is complementary to available classes of medications, and allows for powerful glucose control and the opportunity for modification of the underlying disease. As a SPPARM, INT131 selectively modulates PPAR-gamma, and is ideally positioned to safely improve insulin resistance, addressing an important unmet medical need.

About InteKrin (www.InteKrin.com):

InteKrin Therapeutics is a privately-held clinical-stage drug development company focused on diabetes, obesity and metabolic disease. InteKrin's business strategy is to build a robust portfolio of high value products by in-licensing clinical-stage therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages. InteKrin's team of world-class scientific and medical experts includes veterans from several successful BioPharma organizations, internationally recognized experts in nuclear receptors and metabolism, top scientists formerly with the Food and Drug Administration and key clinical and commercialization leaders.

SOURCE InteKrin Therapeutics Inc.

'/>"/>

SOURCE InteKrin Therapeutics Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related biology technology :

1. InteKrin Therapeutics to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13
2. New Oxygen Biotherapeutics, Inc. Investor Presentation Available on Company Website
3. Reportlinker Adds Stem Cell Therapeutics Markets Report
4. Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report
5. Cell Therapeutics Added to the NASDAQ OMX Global Biotechnology Index
6. Volcano Corporation Announces Schedule of Events for the 2009 Transcatheter Cardiovascular Therapeutics (TCT) Conference
7. Nektar Therapeutics to Host Conference Call to Discuss Todays Announcement of a New Partnership for NKTR-118 and NKTR-119
8. Sorrento Therapeutics, Inc. and QuikByte Software, Inc. Complete Merger
9. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
10. Orexigen(R) Therapeutics to Speak at UBS Global Life Sciences Conference
11. Pervasis Therapeutics Announces $17 Million in Financing and New Board Member